Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Baxter
Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Last Updated: June 29, 2022

CLINICAL TRIALS PROFILE FOR OZEMPIC


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Ozempic

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03596450 ↗ Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial Active, not recruiting Novo Nordisk A/S Phase 4 2018-07-13 The main purpose of this study is to compare the effects of semaglutide (OzempicĀ®) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping a coin) to one of the following treatment groups: Group 1: semaglutide (OzempicĀ®) (by injection into skin) Group 2: standard of care antidiabetic medication (oral or injectable). The participant has an equal chance of being in either of the treatment groups. Neither the participant nor the study doctor or study staff will be able to pick which group the participant is in, but the participant will know which study drug the participant has been assigned to. The study doctor will provide the participant with a prescription for the study diabetes medication based on the treatment group the participant is assigned. The participation will last about 2 years.
NCT03724981 ↗ A Study Comparing the Dulaglutide Pen and the Semaglutide Pen Completed Eli Lilly and Company Phase 4 2018-10-18 In this study participants will try out two different types of drug injection pens (dulaglutide and semaglutide) on a practice pad and decide which device they prefer. No study drug will be administered.
NCT03899402 ↗ Triple Therapy in T1DM Recruiting University of Glasgow Phase 2/Phase 3 2019-05-01 To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.
NCT03899402 ↗ Triple Therapy in T1DM Recruiting State University of New York at Buffalo Phase 2/Phase 3 2019-05-01 To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ozempic

Condition Name

Condition Name for Ozempic
Intervention Trials
Diabetes Mellitus, Type 2 4
Obesity 4
Type2 Diabetes 2
Type 2 Diabetes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ozempic
Intervention Trials
Diabetes Mellitus, Type 2 10
Diabetes Mellitus 9
Prediabetic State 2
Inflammation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ozempic

Trials by Country

Trials by Country for Ozempic
Location Trials
United States 38
Canada 5
United Kingdom 2
Germany 2
New Zealand 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ozempic
Location Trials
Texas 3
Ohio 3
Pennsylvania 3
Kentucky 2
Georgia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ozempic

Clinical Trial Phase

Clinical Trial Phase for Ozempic
Clinical Trial Phase Trials
Phase 4 10
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ozempic
Clinical Trial Phase Trials
Not yet recruiting 8
Recruiting 7
Active, not recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ozempic

Sponsor Name

Sponsor Name for Ozempic
Sponsor Trials
Novo Nordisk A/S 4
State University of New York at Buffalo 2
University of Toronto 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ozempic
Sponsor Trials
Other 31
Industry 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Mallinckrodt
Dow
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.